We have located links that may give you full text access.
Galantamine alleviates senescence of U87 cells induced by beta-amyloid through decreasing ROS production.
Neuroscience Letters 2017 July 14
Galantamine, which is currently used in the treatment of Alzheimer's disease (AD), has been shown to exert a neuroprotective effect against beta-amyloid (Aβ) peptide-induced toxicity, a critical component involved in the pathogenesis of AD. The aim of this study was to examine the effects of galantamine on proliferation, senescence and ROS production in a U87 cell line treated with Aβ. With the use of a Cell Counting Kit-8 and β galactosidase staining assay, we observed that galantamine (0.3μM) pretreatment significantly prevented Aβ1-40-induced cell degradation and senescence. Aβ1-40-induced ROS production and p53 expression were increased as determined by DCF-derived fluorescence using flow cytometry and Western blotting and reduced in response to galantamine pretreatment. Overall, we found that all alterations resulting from Aβ1-40 were reversed by galantamine pretreatment. In addition, we demonstrate that this neuroprotection from galantamine can be blocked by an α7 nAChR antagonist. Taken together, the findings of this study provide a better understanding of the mechanisms underlying the protective effects of galantamine, effects which include antioxidative properties.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app